CoVix SerotopeTM ELISA plate assay to dectect human antibodies to SARS-CoV-2 (COVID-19) now available from InCepix. For Research Use Only!   Please inquire: info@incepix.com phone: (651) 560-2015

Ancell Corporation will continue to supply our important Human Immunology research reagents to the research community as it endeavors to combat the spread of and develop a useful vaccine to the newly discovered deadly coronavirus (Covid-19). Ancell Corporation provides useful tools that allow research scientists to understand how this virus attacks the human immune system.

“A novel and potent brain penetrant inhibitor of extracellular vesicle release” Camilo Rojas, Barbara Slusher, et al. 2019 Brit J Pharmacology 176: 3857-70. Doi: 10.1111/bph.14789. Using high throughput screening of 365,000 compounds, this research group from Johns Hopkins identified “PDDC”, a compound which penetrated brain tissue and inhibited release of murine astrocyte-derived EVs. Ancell anti-human

Check out the exciting new EVix extracellular vesicle research tools from InCepix.com!

Visit Ancell at the 2019 Autumn Immunology Conference at the Downtown Marriott Hotel in Chicago.  We’ll be exhibiting at booth T3  Sat Nov 23 through Sun Nov 24th . 

Neutrophils enact lysis of antibody opsonized target tumor cells by utilizing the CD11b – CD18 interaction to form a cytotoxic synapse which leads to trogocytosis.  This process can be effectively blocked by blockade with either anti-CD11b or anti-CD18 mAbs, but is enhanced when SIRPa – CD47 blockade is employed. “Neutrophils Kill Antibody Opsonized Cancer Cells

“Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus” Stuart J, Stephen H Clarke, et al.  July 1, 2019 Journal of Immunology 203(1): 58-75.  Doi: htpps://doi.org.10.4049/jimmunol.1900043.   Relevant Ancell Products anti-human CD40 mAb Recombinant human CD40-muIg Recombinant human CD154-muCD8

We’ll be exhibiting at the American Immunology Association meeting in San Diego May 10-13 .  Visit us at booth # 417.   

Visit Ancell at booth 4668 at the American Association for Cancer Research meeting in Atlanta Sunday March 31st – Tuesday April 3.  We are co exhibiting with our friends at Incepix!

Anti-CD47 H5F9-G4 antibody blocks CD47 – SIRPa interaction and has been shown to restore anti-cancer immunity in mouse models.  In recent human studies, initial drug dose showed promising effect and was well tolerated in combination with Rituximab(anti-CD20) with side effects of anemia, headache and fatigue.   Relevant Ancell Products New anti-human CD47 mAb